Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Supporting healthcare technology SMEs: an interview with Gary Stapleton, Chairman, Medilink UK

We operate nationwide, giving advice and support to all of our members to allow them to develop and grow their businesses. We do this by giving bespoke support in areas such as innovation - from concept to commercialisation, public relations, international trade – including access to many export markets, market research and guidance on procurement as well as many other areas.

11 Jun 2015

WellSpan Health, CareFusion announce successful implementation of Alaris System in WellSpan hospitals

WellSpan Health and CareFusion, a BD company, today announced the successful implementation of the Alaris System across all four WellSpan hospitals, with WellSpan York Hospital becoming the first hospital ever to simultaneously go-live with new infusion devices and bi-directional interoperability between the infusion device and the electronic health record (EHR).

10 Jun 2015

Researchers develop mesoporous particles for use as drug delivery system

A research group led by MANA Scientist Kohsaku Kawakami, postdoctoral researcher Shaoling Zhang and MANA Principal Investigator Katsuhiko Ariga, at the International Center for Materials Nanoarchitectonics (MANA), NIMS (Sukekatsu Ushioda, President), succeeded in developing porous particles (mesoporous particles) consisting solely of phospholipids, a biological component, that are suitable for use as a drug delivery system.

10 Jun 2015

Scientists study crystallisation process to find new ways to produce pharmaceuticals

Scientists from across the UK and Europe are working together to build a better understanding of the chemical processes behind the creation of crystals with the aim of developing new ways to produce pharmaceuticals.

10 Jun 2015

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.

9 Jun 2015

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction.

8 Jun 2015

Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.

8 Jun 2015

Oxygen regulatory pathway can act to trigger tissue regeneration in mice

A study led by Ellen Heber-Katz, PhD, of the Lankenau Institute for Medical Research, part of Main Line Health, shows that a primordial form of energy production that still exists in mammals can be harnessed to achieve spontaneous tissue regeneration in mice, without the need for added stem cells.

4 Jun 2015

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform.

3 Jun 2015

Study: Intravenous nutrition source may significantly reduce toxicity of platinum-based cancer drugs

A single dose of an FDA-approved intravenous nutrition source may be able to significantly reduce the toxicity and increase the bioavailability of platinum-based cancer drugs, according to a study by Carnegie Mellon University biologists published in Scientific Reports.

3 Jun 2015

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Stempeutics Research, a group company of Manipal Education & Medical Group and a joint venture with Cipla Group, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its drug Stempeucel® for the treatment of Thromboangiitis Obliterans.

2 Jun 2015

BioDelivery Sciences secures additional $20.7M in gross debt funding from MidCap Financial

BioDelivery Sciences International, Inc. announced today that it has secured an additional $20.7 million in gross debt funding from MidCap Financial to bring BDSI's total outstanding debt with MidCap to $30 million in a single senior secured loan.

1 Jun 2015

BioLight Life Sciences reports operational and financial results for Q1 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the first quarter ended March 31, 2015.

1 Jun 2015

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment.

1 Jun 2015

Innovative mini hybrid gamma ray camera improves removal of tumours and lymph nodes

Universities of Leicester and Nottingham to develop mini hybrid gamma ray camera to revolutionise identification and removal of tumours and lymph nodes

1 Jun 2015

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer.

1 Jun 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Caris Life Sciences® today announced the presentation of data from two studies in which researchers utilized Caris Molecular Intelligence®, the company's panomic, comprehensive tumor profiling service, to identify potential therapeutic targets in patients with colorectal and pancreatic cancer subtypes, based on expression of the programmed cell death protein 1 (PD-1) and its ligand, PD-L1.

1 Jun 2015

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Caris Life Sciences today announced the presentation of data from a study in which researchers identified biomarker changes, including key driver mutations, in 89% of metachronous paired glioma tumors, indicating changes in response to therapy as the disease progresses.

1 Jun 2015

Drug Delivery News and Research

Further Reading

Supporting healthcare technology SMEs: an interview with Gary Stapleton, Chairman, Medilink UK

WellSpan Health, CareFusion announce successful implementation of Alaris System in WellSpan hospitals

Researchers develop mesoporous particles for use as drug delivery system

Scientists study crystallisation process to find new ways to produce pharmaceuticals

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

Oxygen regulatory pathway can act to trigger tissue regeneration in mice

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

Study: Intravenous nutrition source may significantly reduce toxicity of platinum-based cancer drugs

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

BioDelivery Sciences secures additional $20.7M in gross debt funding from MidCap Financial

BioLight Life Sciences reports operational and financial results for Q1 2015

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Innovative mini hybrid gamma ray camera improves removal of tumours and lymph nodes

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Must Know Trends for Drug Delivery Systems and the Crucial Role of Materials Testing eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo